| 季秀芳,马艳,木朝宇.血清癌胚抗原、血管内皮生长因子水平与妇科恶性肿瘤合并糖尿病病人术后复发的相关性研究[J].安徽医药,2023,27(10):2041-2045. |
| 血清癌胚抗原、血管内皮生长因子水平与妇科恶性肿瘤合并糖尿病病人术后复发的相关性研究 |
| Correlation between serum CEA and VEGF levels and postoperative recurrence in patients with gynecological malignancies complicated with diabetes mellitus |
| |
| DOI：10.3969/j.issn.1009-6469.2023.10.029 |
| 中文关键词: 生殖器肿瘤，女(雌)性 癌胚抗原 2型糖尿病 血管内皮生长因子 术后复发 |
| 英文关键词: Genital neoplasms, female Carcinoembryonic antigen Type 2 diabetes mellitus Vascular endothelial growth factor Postoperative recurrence |
| 基金项目: |
|
| 摘要点击次数: 942 |
| 全文下载次数: 598 |
| 中文摘要: |
| 目的探究癌胚抗原( CEA)、血管内皮生长因子( VEGF)水平与妇科恶性肿瘤并发 2型糖尿病( T2DM)病人术后复发的关系。方法回顾性研究 2017年 2月至 2021年 2月于淮北矿工总医院行手术治疗的 110例妇科恶性肿瘤并发 T2DM病人为合并 T2DM组，另纳入同期于该院行手术治疗的 55例无 T2DM妇科恶性肿瘤病人为无合并 T2DM组，比较无合并 T2DM组、合并 T2DM组病人血清 CEA，VEGF，糖类抗原( CA)125、CA199水平。对所有妇科恶性肿瘤并发 T2DM病人随访 1年，按其是否发生术后复发分为未复发组( n=72)、复发组( n=38)比较未复发组、复发组妇科恶性肿瘤并发 T2DM病人一般资料及血清 CEA、 VEGF、CA125、CA199水平；分析妇科恶性肿瘤并发，T2DM病人术后复发的影响因素；分析血清 CEA、VEGF对妇科恶性肿瘤并发 T2DM病人术后复发的预测价值。结果合并 T2DM组病人血清 CEA(54.52±18.17)μg/L、VEG(371.93±123.98)ng/L、 CA125(37.48±12.51)U/mL、CA199(41.56±13.85)U/mL水平均高于无合并 T2DM组病人血清 CEA(28.74±9.58)μg/L、VEGF(195.04±65.01)ng/L、CA125(20.76±6.94)U/mL、CA199(28.37±9.46)U/mL(均 P<0.05)；复发组妇科恶性肿瘤并发 T2DM病人血清 CEA、VEGF、糖化血红蛋白( HbA1c)水平均高于未复发组(均 P<0.05)； CEA、VEGF是妇科恶性肿瘤并发 T2DM病人术后复发的影响因素(均 P<0.05)；血清 CEA、VEGF预测妇科恶性肿瘤并发 T2DM病人术后复发的曲线下面积( AUC)为 0.85、0.89，截断值为 72.79 μg/L、397.73 ng/L，灵敏度为 76.3%、78.9%，特异度为 87.5%、89.9%，且血清 CEA、VEGF联合预测妇科恶性肿瘤并发 T2DM病人术后复发的 AUC为 0.96，其灵敏度为 92.1%，特异度为 86.1%。结论 CEA、VEGF在妇科恶性肿瘤并发 T2DM病人血清中水平较高，均与病人术后复发明显相关，且两者联合更有利于预测妇科恶性肿瘤并发 T2DM病人术后复发情况。 |
| 英文摘要: |
| Objective To investigate the relationship between the levels of carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) and postoperative recurrence in patients with gynecological malignancies complicated with type 2 diabetes mellitus (T2DM).Methods A retrospective study a total of 110 patients with gynecological malignant tumor complicated with T2DM whounderwent surgical treatment in our hospital from February 2017 to February 2021 were gathered as the T2DM group. Another 55 patients with gynecological malignancies without T2DM who underwent surgical treatment in our hospital were included in the non-T2DM group. The serum levels of CEA, VEGF, and carbohydrate antigen 125/199 (CA125/CA199) were compared between the non-T2DM group and the T2DM group. All patients with gynecological malignancies complicated with T2DM were followed up for 1 year, and weregrouped into non-recurrence group (n=72) and recurrence group (n=38) according to whether they had postoperative recurrence or not.The general data and the levels of serum CEA, VEGF, CA125 and CA199 in patients with gynecological malignant tumor complicatedwith T2DM in the non-recurrence group and the recurrence group were compared; the influencing factors of postoperative recurrence inpatients with gynecological malignancies complicated with T2DM were analyzed; the predictive value of serum CEA and VEGF for postoperative recurrence in patients with gynecological malignancies complicated with T2DM was analyzed.Results The levels of serum CEA (54.52±18.17)μg/L, VEGF (371.93±123.98) ng/L, CA125 (37.48±12.51) U/mL, CA199 (41.56±13.85) U/mL in patients withT2DM group were higher than those in non-T2DM group CEA (28.74±9.58)μg/L, VEGF (195.04±65.01) ng/L, CA125 (20.76±6.94) U/ mL, CA199 (28.37±9.46) U/mL (all P<0.05); the levels of serum CEA, VEGF and glycosylated hemoglobin (HbA1c) in patients with gynecological malignant tumor complicated with T2DM in the recurrence group were higher than those in the non-recurrence group (all P< 0.05); CEA and VEGF were the influencing factors of postoperative recurrence in patients with gynecological malignancies complicated with T2DM (all P<0.05); the areas under the curve (AUC) of serum CEA and VEGF for predicting postoperative recurrence in patientswith gynecological malignancies complicated with T2DM were 0.850 and 0.893, respectively, the cut-off values were 72.79 μg/L and 397.73 ng/L, and the sensitivities were 76.3% and 78.9%, respectively, the specificities were 87.5% and 89.9%, respectively, and the combined AUC of serum CEA and VEGF for predicting postoperative recurrence in patients with gynecological malignancies complicated with T2DM was 0.96, with a sensitivity of 92.1% and a specificity of 86.1%.Conclusions The serum levels of CEA and VEGF in patients with gynecological malignancies complicated with T2DM are relatively high, and both are obviously correlated with postoperative recurrence. And the combination of the two is more beneficial to predict postoperative recurrence in patients with gynecological malignancies complicated with T2DM. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
